Calidi Biotherapeutics Adds Biopharma Veteran Corsee Sanders to Board — Calidi Biotherapeutics, Inc.

Event summary

Corsee Sanders, Ph.D., joins Calidi Biotherapeutics' Board of Directors as an independent director effective June 17, 2026.
Sanders brings 23 years of experience from Genentech/Roche and leadership roles in Celgene and Bristol Myers Squibb (BMS).
Calidi's RedTail platform aims to deliver genetic medicines to metastatic sites using an engineered oncolytic virus.
CLD-401, the lead candidate, is in IND-enabling studies for non-small cell lung cancer and head and neck cancer.

The big picture

Calidi Biotherapeutics' appointment of Corsee Sanders reflects a strategic move to bolster governance with deep biopharma experience, particularly in CAR-T and clinical operations. The hire comes as Calidi advances its RedTail platform into the clinic, aiming to address high-unmet medical needs in oncology. Sanders' background in large-scale integrations and therapeutic development could prove critical as Calidi navigates partnerships and regulatory pathways.

What we're watching

Clinical Progress: The pace at which CLD-401 advances through IND-enabling studies and into clinical trials will signal Calidi's execution capabilities.
Board Influence: How Corsee Sanders' strategic expertise shapes Calidi's pipeline and partnership strategy, particularly in integrating novel therapeutics.
Market Positioning: Whether Calidi can differentiate its RedTail platform in a competitive landscape of targeted genetic medicines.